Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome

American Journal of Cardiology

Volumn 108, Issue 9, 2011, Pages 1244-1251

  Friedland, Sayuri ^a   Eisenberg, Mark J ^a   Shimony, Avi ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; COCHRANE LIBRARY; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; EMBASE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; MORTALITY; MYOCARDIAL BLUSH; MYOCARDIAL DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TARGET VESSEL REVASCULARIZATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CORONARY CIRCULATION; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TYROSINE;

EID: 80054705415     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.06.039     Document Type: Article

References (30)

1. A. Iversen, S. Galatius, and J.S. Jensen The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percutaneous coronary intervention; intravenous versus intracoronary Curr Cardiol Rev 4 2008 293 299
2. R. Chun, B.A. Orser, and M. Madan Platelet glycoprotein IIb/IIIa inhibitors: overview and implications for the anesthesiologist Anesth Analg 95 2002 879 888
3. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
4. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and H.J. McQuay Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12 (Pubitemid 26120810)
5. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
6. R. Erdim, D. Erciyes, S. Görmez, K.O. Karabay, A.B. Catakolu, V. Aytekin, C. Demirolu, and M. Glbaran Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention Anadolu Kardiyol Derg 10 2010 340 345
7. A.K. Kakkar, A. Moustapha, H.G. Hanley, M. Weiss, G. Caldito, P. Misra, P.C. Reddy, and N. Tandon Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting Catheter Cardiovasc Interv 61 2004 31 34 (Pubitemid 38036787)
8. D.S. Pinto, A.J. Kirtane, N.A. Ruocco, A.J. Deibele, A. Shui, J. Buros, S.A. Murphy, and C.M. Gibson Administration of intracoronary eptifibatide during ST-elevation myocardial infarction Am J Cardiol 96 2005 1494 1497 (Pubitemid 41690166)
9. J. Wöhrle, T. Nusser, C. Mayer, M. Kochs, and V. Hombach Intracoronary application of abciximab in patients with ST-elevation myocardial infarction Eurointervention 3 2008 465 469
10. J. Wöhrle, O.C. Grebe, T. Nusser, E. Al-Khayer, S. Schaible, M. Kochs, V. Hombach, and M. Höher Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty Circulation 107 2003 1840 1843 (Pubitemid 36444121)
11. A.J. Deibele, A.J. Kirtane, D.S. Pinto, M.J. Lucca, C. Neva, A. Shui, S.A. Murphy, J.E. Tcheng, and C.M. Gibson Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina J Thromb Thrombolysis 22 2006 47 50 (Pubitemid 43923001)
12. E. Romagnoli, F. Burzotta, C. Trani, M.A. Mazzari, G.G. Biondi-Zoccai, M. De Vita, F. Giannico, G. Niccoli, F. Prati, A.G. Rebuzzi, R. Mongiardo, and F. Crea Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI Int J Cardiol 105 2005 250 255 (Pubitemid 41605072)
13. O.F. Bertrand, J. Rodés-Cabau, E. Larose, C.M. Nguyen, J.P. Déry, G. Proulx, L. Roy, P. Poirier, O. Costerousse, and R. De Larochellire Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: a sub-analysis of the EASY trial Int J Cardiol 136 2009 165 170
14. I. Eitel, S. Desch, K. Schindler, G. Fuernau, G. Schuler, and H. Thiele Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction Int J Cardiol 2010 [Epub ahead of print].
15. H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Frnau, E. Grebe, S. Erbs, A. Linke, S. Möbius-Winkler, D. Kivelitz, and G. Schuler Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial Circulation 118 2008 49 57
16. I. Eitel, J. Friedenberger, G. Fuernau, A. Dumjahn, S. Desch, G. Schuler, and H. Thiele Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function: the randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI) Clin Res Cardiol 100 2010 425 432
17. O.F. Bertrand, J. Rodés-Cabau, E. Larose, S. Rinfret, V. Gaudreault, G. Proulx, G. Barbeau, J.P. Déry, O. Gleeton, C. Manh-Nguyen, B. Nol, L. Roy, O. Costerousse, and R. De Larochellire Early Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study Am J Cardiol 105 2010 1520 1527
18. A.J. Deibele, L.K. Jennings, J.E. Tcheng, C. Neva, A.D. Earhart, and C.M. Gibson Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial Circulation 121 2010 784 791
19. Y.L. Gu, M.A. Kampinga, W.G. Wieringa, M.L. Fokkema, M.W. Nijsten, H.L. Hillege, A.F. van den Heuvel, E.S. Tan, G. Pundziute, R. van der Werf, S. Hoseyni Guyomi, I.C. van der Horst, F. Zijlstra, and B.J. de Smet Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary versus Intravenous Abciximab Administration during Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial Circulation 122 2010 2709 2717
20. A. Iversen, U. Abildgaard, A. Galloe, P.R. Hansen, S. Galatius, J.K. Madsen, T. Engstroem, S. Pedersen, K.S. Jensen, and J.S. Jensen Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: A randomized trial J Interv Cardiol 24 2011 105 111
21. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, P. Avanzas, F. Bosa-Ojeda, S. Samimi-Fard, F. Marrero-Rodriguez, and J.C. Kaski Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary interventioneffects on soluble CD40 ligand concentrations Atherosclerosis 206 2009 523 527
22. T.G. Wu, Q. Zhao, W.G. Huang, J.R. Wei, S.W. Chen, J. Zhao, L.P. Huang, and L.X. Wang Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome Circ J 72 2008 1605 1609
23. X.C. Yang, D.P. Zhang, L.F. Wang, L. Xu, Y.G. Ge, H.S. Wang, W.M. Li, Z.H. Ni, K. Xia, Y. Lian, Y.L. Xue, and L.X. Ma [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention] Zhonghua Xin Xue Guan Bing Za Zhi 35 2007 517 522
24. J.G. Galache Osuna, J. Sánchez-Rubio, I. Calvo, J.A. Diarte, A. Lukic, and L.J. Placer [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial] Rev Esp Cardiol 59 2006 567 574 (Pubitemid 44203201)
25. F. Bellandi, M. Maioli, M. Gallopin, A. Toso, and R.P. Dabizzi Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention Catheter Cardiovasc Interv 62 2004 186 192 (Pubitemid 38788695)
26. W. Pan, L.F. Wang, J.H. Yu, Y. Fan, S.S. Yang, L.J. Zhou, Y. Li, and W.M. Li Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction Chin Med J (Engl) 122 2009 2718 2723
27. S. Sharma, R. Makkar, and J. Lardizabal Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach? J Cardiovasc Pharmacol Ther 11 2006 136 141 (Pubitemid 44449103)
28. P.R. Hansen, A. Iversen, and J. Abdulla Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis J Invasive Cardiol 22 2010 278 282
29. D. Antoniucci Differences among GP IIb/IIIa inhibitors: different clinical benefits in nonST-segment elevation acute coronary syndrome percutaneous coronary intervention patients Eur Heart J Suppl 9 2007 A32 A36
30. H.S. Gurm, U. Tamhane, P. Meier, P.M. Grossman, S. Chetcuti, and E.R. Bates A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials Circ Cardiovasc Interv 2 2009 230 236